BioAtla, Inc. Reports CMO Resignation; CEO/CFO Retention & Performance Bonuses

What Happened
BioAtla, Inc. filed an 8‑K reporting that Chief Medical Officer Dr. Eric Sievers resigned effective September 25, 2026 and entered a consulting agreement dated September 25, 2026. The company’s board also approved revised retention bonus arrangements for CEO Jay M. Short, Ph.D., and CFO Christian Vasquez and a new performance bonus opportunity for both executives tied to capital‑raising and financial milestones.

Key Details

• Dr. Eric Sievers resigned as CMO on September 25, 2026 and will consult through a Consulting Agreement (dated Sept 25, 2026) that runs through June 30, 2027 unless extended.
  • Eligible for a one‑time payment of $159,000 if certain capital raising milestones are met by December 31, 2026.
  • After January 1, 2027 through June 30, 2027, consulting pay will be hourly at a rate proportional to his base salary at separation.
• CFO Christian Vasquez: Board reinstated Milestone #2 only (deadline Dec 31, 2026) with a target retention bonus of $148,888 (40% of base salary).
  • Payout is on a sliding scale: 80%–120% of target for +/-20% performance around the milestone; >20% shortfall = no payout. Payable by Jan 31, 2027; must be employed and in good standing.
• CEO Jay Short: reinstated retention bonus for the same milestones due Dec 31, 2026 with a target of $440,892 (60% of base salary).
  • No sliding scale — must achieve 100% of the milestone to receive any payout. Payable by Jan 30, 2027; must be employed and in good standing.
• Performance Bonus for CEO and CFO: approved Sept 24, 2026, contingent on milestones by March 31, 2027.
  • Vasquez target: $75,000. Short target: $220,000. Payable by April 30, 2027; recipients must be employed and in good standing.

Why It Matters
This filing shows a leadership change in the medical function while keeping continuity through a paid consulting arrangement, and it sets out near‑term cash commitments tied to capital‑raising and financial milestones. For investors, the items are notable because they (1) reveal management incentives tied to a strategic/financing process, (2) create potential cash outflows in late 2026 and early 2027 if milestones are met, and (3) indicate the board’s focus on completing specific capital or financial goals. The payments are contingent and subject to employment/in‑good‑standing requirements, so actual cash impact depends on milestone achievement.